Review



ox86 agonist antibody  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Bio X Cell ox86 agonist antibody
    Ox86 Agonist Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 103 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/InVivoMAb+anti-mouse+OX40/pm41895288-319-64-69
    Average 95 stars, based on 103 article reviews
    ox86 agonist antibody - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Therapeutic potential of co-signaling receptor modulation in hepatitis B.
    Article Snippet: In selected experiments, mice were splenectomized and injected intraperitoneally (i.p.) with 100 mg of antiCD62L monoclonal antibody (clone MEL-14, BioXcell #BE0021) in PBS 4 h prior to cell injection. .. Splenectomy was performed according to standard protocols.56 In indicated experiments, recipient mice were injected i.p. with wither 100mg of anti-mouse PD-1 (clone RMP1-14, Biolegend #114114), anti-mouse LAG-3 (clone C9B7W, BioXcell #BE0174), anti-mouse CTLA-4 (clone 9H10, BioXcell #BE0131), anti-mouse ICOS (clone C398.4A, BioXcell #BE0353), anti-mouse OX40 (clone OX-86, BioXcell #BE0031) or anti-mouse 4-1BB (clone 3H3, BioXcell #BE0239) antibodies at saturating concentration one day after T cell transfer, unless otherwise indicated. ..

    Article Title: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Article Snippet: .. Anti-mouse PD-L1: clone 80 mIgG1 D265A (AstraZeneca), anti-rat PD-L1: clone 10F.9G2 (BioXcell), Mouse GITRL fusion protein [26], anti-mouse OX40: Clone OX86 mIgG2a (AstraZeneca), anti-mouse NK1.1: clone PK136 mIgG2a (BioXcell) or corresponding isotype controls (NIP, AstraZeneca) were injected via intraperitoneal (IP) injection. .. Anti-mouse PD-L1: clone 80 mIgG1 D265A (AstraZeneca), anti-rat PD-L1: clone 10F.9G2 (BioXcell), Mouse GITRL fusion protein [26], anti-mouse OX40: Clone OX86 mIgG2a (AstraZeneca), anti-mouse NK1.1: clone PK136 mIgG2a (BioXcell) or corresponding isotype controls (NIP, AstraZeneca) were injected via intraperitoneal (IP) injection.

    Article Title: Therapeutic potential of co-signaling receptor modulation in hepatitis B
    Article Snippet: .. In indicated experiments, recipient mice were injected i.p. with wither 100μg of anti-mouse PD-1 (clone RMP1-14, Biolegend #114114), anti-mouse LAG-3 (clone C9B7W, BioXcell #BE0174), anti-mouse CTLA-4 (clone 9H10, BioXcell #BE0131), anti-mouse ICOS (clone C398.4A, BioXcell #BE0353), anti-mouse OX40 (clone OX-86, BioXcell #BE0031) or anti-mouse 4-1BB (clone 3H3, BioXcell #BE0239) antibodies at saturating concentration one day after T cell transfer, unless otherwise indicated. ..

    Concentration Assay:

    Article Title: Therapeutic potential of co-signaling receptor modulation in hepatitis B.
    Article Snippet: In selected experiments, mice were splenectomized and injected intraperitoneally (i.p.) with 100 mg of antiCD62L monoclonal antibody (clone MEL-14, BioXcell #BE0021) in PBS 4 h prior to cell injection. .. Splenectomy was performed according to standard protocols.56 In indicated experiments, recipient mice were injected i.p. with wither 100mg of anti-mouse PD-1 (clone RMP1-14, Biolegend #114114), anti-mouse LAG-3 (clone C9B7W, BioXcell #BE0174), anti-mouse CTLA-4 (clone 9H10, BioXcell #BE0131), anti-mouse ICOS (clone C398.4A, BioXcell #BE0353), anti-mouse OX40 (clone OX-86, BioXcell #BE0031) or anti-mouse 4-1BB (clone 3H3, BioXcell #BE0239) antibodies at saturating concentration one day after T cell transfer, unless otherwise indicated. ..

    Article Title: Therapeutic potential of co-signaling receptor modulation in hepatitis B
    Article Snippet: .. In indicated experiments, recipient mice were injected i.p. with wither 100μg of anti-mouse PD-1 (clone RMP1-14, Biolegend #114114), anti-mouse LAG-3 (clone C9B7W, BioXcell #BE0174), anti-mouse CTLA-4 (clone 9H10, BioXcell #BE0131), anti-mouse ICOS (clone C398.4A, BioXcell #BE0353), anti-mouse OX40 (clone OX-86, BioXcell #BE0031) or anti-mouse 4-1BB (clone 3H3, BioXcell #BE0239) antibodies at saturating concentration one day after T cell transfer, unless otherwise indicated. ..

    Chromatin Immunoprecipitation:

    Article Title: Nanoparticle-based modulation of CD4 + T cell effector and helper functions enhances adoptive immunotherapy
    Article Snippet: .. 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Unlabeled antibodies: anti-mouse CD3e clone 145-2C11 (BioXcell, cat. BE0001-1), anti-mouse CD28 clone 37.51 (BioXcell, cat. BE0015-1), anti-mouse OX40 clone OX-86 (BioXcell, cat. BE0031), anti-mouse IFN#R clone GR-20 (BioXcell, cat. BE0029), anti-mouse IA/I-E clone M5/114 (BioXcell, cat. BE0108), anti-mouse TNF! clone XT3.11 (BioXcell, cat. BE0058), and anti-mouse IL-10 clone JES5-2A5 (BioXcell, cat. BE0049), anti-human CD3 clone OKT-3 (BioXcell, cat. BE0001-2), anti-human CD28 clone 9.3 (BioXcell, cat. BE0248). ..

    Flow Cytometry:

    Article Title: Nanoparticle-based modulation of CD4 + T cell effector and helper functions enhances adoptive immunotherapy
    Article Snippet: .. 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Unlabeled antibodies: anti-mouse CD3e clone 145-2C11 (BioXcell, cat. BE0001-1), anti-mouse CD28 clone 37.51 (BioXcell, cat. BE0015-1), anti-mouse OX40 clone OX-86 (BioXcell, cat. BE0031), anti-mouse IFN#R clone GR-20 (BioXcell, cat. BE0029), anti-mouse IA/I-E clone M5/114 (BioXcell, cat. BE0108), anti-mouse TNF! clone XT3.11 (BioXcell, cat. BE0058), and anti-mouse IL-10 clone JES5-2A5 (BioXcell, cat. BE0049), anti-human CD3 clone OKT-3 (BioXcell, cat. BE0001-2), anti-human CD28 clone 9.3 (BioXcell, cat. BE0248). ..

    Magnetic Resonance Imaging:

    Article Title: Nanoparticle-based modulation of CD4 + T cell effector and helper functions enhances adoptive immunotherapy
    Article Snippet: .. 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Unlabeled antibodies: anti-mouse CD3e clone 145-2C11 (BioXcell, cat. BE0001-1), anti-mouse CD28 clone 37.51 (BioXcell, cat. BE0015-1), anti-mouse OX40 clone OX-86 (BioXcell, cat. BE0031), anti-mouse IFN#R clone GR-20 (BioXcell, cat. BE0029), anti-mouse IA/I-E clone M5/114 (BioXcell, cat. BE0108), anti-mouse TNF! clone XT3.11 (BioXcell, cat. BE0058), and anti-mouse IL-10 clone JES5-2A5 (BioXcell, cat. BE0049), anti-human CD3 clone OKT-3 (BioXcell, cat. BE0001-2), anti-human CD28 clone 9.3 (BioXcell, cat. BE0248). ..

    Biomarker Discovery:

    Article Title: Nanoparticle-based modulation of CD4 + T cell effector and helper functions enhances adoptive immunotherapy
    Article Snippet: .. 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Unlabeled antibodies: anti-mouse CD3e clone 145-2C11 (BioXcell, cat. BE0001-1), anti-mouse CD28 clone 37.51 (BioXcell, cat. BE0015-1), anti-mouse OX40 clone OX-86 (BioXcell, cat. BE0031), anti-mouse IFN#R clone GR-20 (BioXcell, cat. BE0029), anti-mouse IA/I-E clone M5/114 (BioXcell, cat. BE0108), anti-mouse TNF! clone XT3.11 (BioXcell, cat. BE0058), and anti-mouse IL-10 clone JES5-2A5 (BioXcell, cat. BE0049), anti-human CD3 clone OKT-3 (BioXcell, cat. BE0001-2), anti-human CD28 clone 9.3 (BioXcell, cat. BE0248). ..

    other:

    Article Title: TCR-independent CD137 (4–1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation
    Article Snippet: Anti-mouse OX40 , Bio X Cell , Cat#: BE0031 RRID: AB_1107592.



    Similar Products

    95
    Bio X Cell ox86 agonist antibody
    Ox86 Agonist Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/InVivoMAb+anti-mouse+OX40/pm41895288-319-64-69
    Average 95 stars, based on 1 article reviews
    ox86 agonist antibody - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    Bio X Cell agonistic anti ox40
    Agonistic Anti Ox40, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/InVivoMAb+anti-mouse+OX40/pm41486690-190-22-26
    Average 95 stars, based on 1 article reviews
    agonistic anti ox40 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc anti mouse ox40
    High dose SMC remodels the GBM microenvironment . A) Experimental outline for IHC and flow cytometric analysis of IC GL261 tumors following high dose LCL161 treatments. Mice bearing IC GL261 tumors were treated orally 2×/week or 5×/week for two weeks with 100mg/kg LCL161. B) At day 18 post-implant, brains were processed for immunohistochemical staining of IBA1, TMEM119, and Arginase-1 (ARG1). Scale bar: 500 µm. C–G) Total IBA1 + cells (C) and TMEM119 subsets (D–G) within identified tumor margins were quantified and plotted as a percentage of total DAPI detections or as a fraction of total IBA1 + cells. H) Mice bearing IC GL261 tumors were stained for CD3, CD8, PD-1, TIM3 and <t>OX40</t> expression. I–L) Total CD3 + cell counts, CD8 + subsets, and expression of TIM3 were quantified and plotted as either percent of total DAPI detections within tumor margins or as a proportion of total CD3+ events. N = 2 vehicle, N = 4 2d/wk, N = 5 5d/wk LCL161 treated animals per group *P < 0.05; ***P < 0.001; via one-way ANOVA using Tukey’s HSD multiple comparison test.
    Anti Mouse Ox40, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/OX40+Mouse+mAb/pmc12901662-51-0-7
    Average 93 stars, based on 1 article reviews
    anti mouse ox40 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc mouse anti human ox40
    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, <t>OX40,</t> and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
    Mouse Anti Human Ox40, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/OX40+Mouse+mAb/pmc12776187-91-17-26
    Average 93 stars, based on 1 article reviews
    mouse anti human ox40 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    Proteintech mouse anti human ox40
    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, <t>OX40,</t> and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
    Mouse Anti Human Ox40, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/CD134%2FOX40+Antibody/pmc12776187-91-17-34
    Average 94 stars, based on 1 article reviews
    mouse anti human ox40 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems anti ox40 ligand
    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, <t>OX40,</t> and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
    Anti Ox40 Ligand, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/Mouse+OX40+Ligand%2FTNFSF4+PE-conjugated+Antibody/pm41451507-69-119-127
    Average 93 stars, based on 1 article reviews
    anti ox40 ligand - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    Bio X Cell free dox αox40
    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, <t>OX40,</t> and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
    Free Dox αox40, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/InVivoMAb+anti-mouse+OX40/pm41308751-92-21-32
    Average 95 stars, based on 1 article reviews
    free dox αox40 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    93
    Bio X Cell antimouse cd4 gk1 5
    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, <t>OX40,</t> and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
    Antimouse Cd4 Gk1 5, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/InVivoPlus+anti-mouse+OX40/pm41287279-265-9-12
    Average 93 stars, based on 1 article reviews
    antimouse cd4 gk1 5 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    Bio X Cell anti mouse cd4 gk1 5
    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, <t>OX40,</t> and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.
    Anti Mouse Cd4 Gk1 5, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mouse+ox40/InVivoPlus+anti-mouse+OX40/pmc12952256-331-9-12
    Average 93 stars, based on 1 article reviews
    anti mouse cd4 gk1 5 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    High dose SMC remodels the GBM microenvironment . A) Experimental outline for IHC and flow cytometric analysis of IC GL261 tumors following high dose LCL161 treatments. Mice bearing IC GL261 tumors were treated orally 2×/week or 5×/week for two weeks with 100mg/kg LCL161. B) At day 18 post-implant, brains were processed for immunohistochemical staining of IBA1, TMEM119, and Arginase-1 (ARG1). Scale bar: 500 µm. C–G) Total IBA1 + cells (C) and TMEM119 subsets (D–G) within identified tumor margins were quantified and plotted as a percentage of total DAPI detections or as a fraction of total IBA1 + cells. H) Mice bearing IC GL261 tumors were stained for CD3, CD8, PD-1, TIM3 and OX40 expression. I–L) Total CD3 + cell counts, CD8 + subsets, and expression of TIM3 were quantified and plotted as either percent of total DAPI detections within tumor margins or as a proportion of total CD3+ events. N = 2 vehicle, N = 4 2d/wk, N = 5 5d/wk LCL161 treated animals per group *P < 0.05; ***P < 0.001; via one-way ANOVA using Tukey’s HSD multiple comparison test.

    Journal: Neuro-Oncology Advances

    Article Title: Enhanced glioblastoma immunotherapy via SMAC mimetic dose escalation and TGFβ blockade

    doi: 10.1093/noajnl/vdaf253

    Figure Lengend Snippet: High dose SMC remodels the GBM microenvironment . A) Experimental outline for IHC and flow cytometric analysis of IC GL261 tumors following high dose LCL161 treatments. Mice bearing IC GL261 tumors were treated orally 2×/week or 5×/week for two weeks with 100mg/kg LCL161. B) At day 18 post-implant, brains were processed for immunohistochemical staining of IBA1, TMEM119, and Arginase-1 (ARG1). Scale bar: 500 µm. C–G) Total IBA1 + cells (C) and TMEM119 subsets (D–G) within identified tumor margins were quantified and plotted as a percentage of total DAPI detections or as a fraction of total IBA1 + cells. H) Mice bearing IC GL261 tumors were stained for CD3, CD8, PD-1, TIM3 and OX40 expression. I–L) Total CD3 + cell counts, CD8 + subsets, and expression of TIM3 were quantified and plotted as either percent of total DAPI detections within tumor margins or as a proportion of total CD3+ events. N = 2 vehicle, N = 4 2d/wk, N = 5 5d/wk LCL161 treated animals per group *P < 0.05; ***P < 0.001; via one-way ANOVA using Tukey’s HSD multiple comparison test.

    Article Snippet: Anti-mouse OX40 , 1:50, AR pH6 , Cell Signaling , 61637S.

    Techniques: Immunohistochemical staining, Staining, Expressing, Comparison

    SMCs upregulate T-cell activation markers in peripheral lymphoid organs but not in brain tumors . A) Flow cytometric analysis of CD3 (BV786), CD4 (AF700) and CD8 (FITC) in spleen from mice bearing GL261 tumors and treated with vehicle or 100mg/kg LCL161 2d/week. B) Quantification of live cells CD3 + in spleen and lymph nodes across indicated treatment groups. N = 2 for unimplanted, N = 5 per remaining treatment groups. *P < 0.05; **P < 0.01 via two-way ANOVA using Tukey’s HSD multiple comparison test. C) Proportion of CD3 + CD4 + cells in indicated organ expressing CD25 receiving indicated treatments. D, E) MFI of OX40 (D) and CD69 (E) on CD3 + CD4 + and CD3 + CD8 + cells in indicated organ receiving indicated treatment. F) PD-1 expression of splenic CD8+ T-cells from mice with or without IC GL261 tumors, quantified in (G). H) MFI of LAG3 expression in CD3 + cells in spleen. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 via two-way ANOVA using Tukey’s HSD multiple comparison test. I–L) Flow cytometric analysis of CD3 positivity and subsets in resected GL261 tumors following treatment with vehicle or 100mg/kg LCL161 2d/wk. J) Quantification of proportion of live cells CD3 + . L) Ratio of CD4: CD8 cells among CD3 + populations.

    Journal: Neuro-Oncology Advances

    Article Title: Enhanced glioblastoma immunotherapy via SMAC mimetic dose escalation and TGFβ blockade

    doi: 10.1093/noajnl/vdaf253

    Figure Lengend Snippet: SMCs upregulate T-cell activation markers in peripheral lymphoid organs but not in brain tumors . A) Flow cytometric analysis of CD3 (BV786), CD4 (AF700) and CD8 (FITC) in spleen from mice bearing GL261 tumors and treated with vehicle or 100mg/kg LCL161 2d/week. B) Quantification of live cells CD3 + in spleen and lymph nodes across indicated treatment groups. N = 2 for unimplanted, N = 5 per remaining treatment groups. *P < 0.05; **P < 0.01 via two-way ANOVA using Tukey’s HSD multiple comparison test. C) Proportion of CD3 + CD4 + cells in indicated organ expressing CD25 receiving indicated treatments. D, E) MFI of OX40 (D) and CD69 (E) on CD3 + CD4 + and CD3 + CD8 + cells in indicated organ receiving indicated treatment. F) PD-1 expression of splenic CD8+ T-cells from mice with or without IC GL261 tumors, quantified in (G). H) MFI of LAG3 expression in CD3 + cells in spleen. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 via two-way ANOVA using Tukey’s HSD multiple comparison test. I–L) Flow cytometric analysis of CD3 positivity and subsets in resected GL261 tumors following treatment with vehicle or 100mg/kg LCL161 2d/wk. J) Quantification of proportion of live cells CD3 + . L) Ratio of CD4: CD8 cells among CD3 + populations.

    Article Snippet: Anti-mouse OX40 , 1:50, AR pH6 , Cell Signaling , 61637S.

    Techniques: Activation Assay, Comparison, Expressing

    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Immunohistochemical staining, Staining, Immunofluorescence, Expressing, Flow Cytometry, Standard Deviation, Immunohistochemistry

    OX40L/IL-2 stimulation of PBMCs and TILs. (A) Flow cytometry analyses of T cell expression upon stimulation with different concentration of OX40L/IL-2. (B) Flow cytometry analyses of PBMCs and TILs upon stimulation with IL-2, OX40L, and OX40L/IL-2. (C) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in PBMCs. (D) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01; ***, P<0.001. ANOVA, analysis of variance; IFN-γ, interferon-gamma; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes; TNF-α, tumor necrosis factor-alpha.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: OX40L/IL-2 stimulation of PBMCs and TILs. (A) Flow cytometry analyses of T cell expression upon stimulation with different concentration of OX40L/IL-2. (B) Flow cytometry analyses of PBMCs and TILs upon stimulation with IL-2, OX40L, and OX40L/IL-2. (C) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in PBMCs. (D) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01; ***, P<0.001. ANOVA, analysis of variance; IFN-γ, interferon-gamma; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes; TNF-α, tumor necrosis factor-alpha.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Flow Cytometry, Expressing, Concentration Assay, Standard Deviation

    Apoptotic effect of OX40L and IL-2 on co-culture of PBMCs or TILs from gastric cancer patients with gastric cancer primary cells. (A) H&E staining and immunohistochemistry labeling with a cytokeratin antibodies of primary gastric cancer cells. (B) Flow cytometry analyses of apoptosis in PBMCs co-cultured with primary gastric cancer cells alone, and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. (C) Flow cytometry analyses of apoptosis in TILs co-cultured with primary gastric cancer cells alone and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; H&E, hematoxylin & eosin; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: Apoptotic effect of OX40L and IL-2 on co-culture of PBMCs or TILs from gastric cancer patients with gastric cancer primary cells. (A) H&E staining and immunohistochemistry labeling with a cytokeratin antibodies of primary gastric cancer cells. (B) Flow cytometry analyses of apoptosis in PBMCs co-cultured with primary gastric cancer cells alone, and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. (C) Flow cytometry analyses of apoptosis in TILs co-cultured with primary gastric cancer cells alone and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; H&E, hematoxylin & eosin; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Co-Culture Assay, Staining, Immunohistochemistry, Labeling, Flow Cytometry, Cell Culture, Standard Deviation

    Apoptotic effects of infectious adenovirus pAd-IL-2-OX40L on co-cultured gastric cancer patients TILs and gastric cancer primary cells. (A) Schematic presentation of adenoviral vector construction expressing OX40L/IL-2 and transfection of HEK293K cells with subsequent production of infectious AdV vector particles. (B) Flow cytometry analyses of gastric cancer primary cells, gastric cancer primary cells infected with pAd-IL-2-OX40L, gastric cancer primary cells and TILs, and co-culture of gastric cancer primary cells infected with pAd-IL-2-OX40L and TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; IL-2, interleukin-2; OX40L, OX40 ligand; TILs, tumor-infiltrating lymphocytes.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: Apoptotic effects of infectious adenovirus pAd-IL-2-OX40L on co-cultured gastric cancer patients TILs and gastric cancer primary cells. (A) Schematic presentation of adenoviral vector construction expressing OX40L/IL-2 and transfection of HEK293K cells with subsequent production of infectious AdV vector particles. (B) Flow cytometry analyses of gastric cancer primary cells, gastric cancer primary cells infected with pAd-IL-2-OX40L, gastric cancer primary cells and TILs, and co-culture of gastric cancer primary cells infected with pAd-IL-2-OX40L and TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; IL-2, interleukin-2; OX40L, OX40 ligand; TILs, tumor-infiltrating lymphocytes.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Cell Culture, Plasmid Preparation, Expressing, Transfection, Flow Cytometry, Infection, Co-Culture Assay, Standard Deviation

    Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: Immunohistochemical and flow cytometric analysis of gastric cancer tissue. (A) H&E histochemical staining of tumor-free area (left), tumor margin (middle), and gastric tumor site (right). (B) Representative IHC images for CD3 + , CD4 + , CD8 + , FOXP3, OX40, and OX40L in tumor-free area (left column), tumor margin (middle column), and gastric tumor site (right column) sections. (C) Immunofluorescence staining for the co-expression of CD3 + and OX40 in gastric cancer with anti-CD3 and anti-OX40 antibodies and DAPI for nuclear staining. (D) Flow cytometry analysis of OX40 expression in CD3 cells obtained from PBMC of gastric cancer patients (upper panel) and OX40 expression on CD3 on TILs in gastric cancer patients (low panel). Statistical analysis of all data were performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; ***, P<0.001. ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; H&E, hematoxylin & eosin; IHC, immunohistochemistry; OX40L, OX40 ligand; PBMC, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Immunohistochemical staining, Staining, Immunofluorescence, Expressing, Flow Cytometry, Standard Deviation, Immunohistochemistry

    OX40L/IL-2 stimulation of PBMCs and TILs. (A) Flow cytometry analyses of T cell expression upon stimulation with different concentration of OX40L/IL-2. (B) Flow cytometry analyses of PBMCs and TILs upon stimulation with IL-2, OX40L, and OX40L/IL-2. (C) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in PBMCs. (D) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01; ***, P<0.001. ANOVA, analysis of variance; IFN-γ, interferon-gamma; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes; TNF-α, tumor necrosis factor-alpha.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: OX40L/IL-2 stimulation of PBMCs and TILs. (A) Flow cytometry analyses of T cell expression upon stimulation with different concentration of OX40L/IL-2. (B) Flow cytometry analyses of PBMCs and TILs upon stimulation with IL-2, OX40L, and OX40L/IL-2. (C) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in PBMCs. (D) Expression at mRNA and secreted protein level of TNF-α, IFN-γ, Perforin, and Granzyme B after OX40L/IL-2 stimulation in TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01; ***, P<0.001. ANOVA, analysis of variance; IFN-γ, interferon-gamma; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes; TNF-α, tumor necrosis factor-alpha.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Flow Cytometry, Expressing, Concentration Assay, Standard Deviation

    Apoptotic effect of OX40L and IL-2 on co-culture of PBMCs or TILs from gastric cancer patients with gastric cancer primary cells. (A) H&E staining and immunohistochemistry labeling with a cytokeratin antibodies of primary gastric cancer cells. (B) Flow cytometry analyses of apoptosis in PBMCs co-cultured with primary gastric cancer cells alone, and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. (C) Flow cytometry analyses of apoptosis in TILs co-cultured with primary gastric cancer cells alone and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; H&E, hematoxylin & eosin; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: Apoptotic effect of OX40L and IL-2 on co-culture of PBMCs or TILs from gastric cancer patients with gastric cancer primary cells. (A) H&E staining and immunohistochemistry labeling with a cytokeratin antibodies of primary gastric cancer cells. (B) Flow cytometry analyses of apoptosis in PBMCs co-cultured with primary gastric cancer cells alone, and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. (C) Flow cytometry analyses of apoptosis in TILs co-cultured with primary gastric cancer cells alone and after stimulation with either IL-2, or OX40L, or OX40L/IL-2. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; H&E, hematoxylin & eosin; IL-2, interleukin-2; OX40L, OX40 ligand; PBMCs, peripheral blood mononuclear cells; TILs, tumor-infiltrating lymphocytes.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Co-Culture Assay, Staining, Immunohistochemistry, Labeling, Flow Cytometry, Cell Culture, Standard Deviation

    Apoptotic effects of infectious adenovirus pAd-IL-2-OX40L on co-cultured gastric cancer patients TILs and gastric cancer primary cells. (A) Schematic presentation of adenoviral vector construction expressing OX40L/IL-2 and transfection of HEK293K cells with subsequent production of infectious AdV vector particles. (B) Flow cytometry analyses of gastric cancer primary cells, gastric cancer primary cells infected with pAd-IL-2-OX40L, gastric cancer primary cells and TILs, and co-culture of gastric cancer primary cells infected with pAd-IL-2-OX40L and TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; IL-2, interleukin-2; OX40L, OX40 ligand; TILs, tumor-infiltrating lymphocytes.

    Journal: Translational Cancer Research

    Article Title: OX40L and IL-2 combination strategy for gastric cancer immunotherapy

    doi: 10.21037/tcr-2025-707

    Figure Lengend Snippet: Apoptotic effects of infectious adenovirus pAd-IL-2-OX40L on co-cultured gastric cancer patients TILs and gastric cancer primary cells. (A) Schematic presentation of adenoviral vector construction expressing OX40L/IL-2 and transfection of HEK293K cells with subsequent production of infectious AdV vector particles. (B) Flow cytometry analyses of gastric cancer primary cells, gastric cancer primary cells infected with pAd-IL-2-OX40L, gastric cancer primary cells and TILs, and co-culture of gastric cancer primary cells infected with pAd-IL-2-OX40L and TILs. Statistical analysis of all data was performed using one-way ANOVA. Data are shown as mean ± standard deviation. ns, nonsignificant; *, P<0.05; **, P<0.01. ANOVA, analysis of variance; IL-2, interleukin-2; OX40L, OX40 ligand; TILs, tumor-infiltrating lymphocytes.

    Article Snippet: Immunohistochemistry (IHC) analyses were performed using specific primary rabbit anti-human CD3 monoclonal antibody (Proteintech Group, Wuhan, China), mouse anti-human OX40 and rabbit anti-human OX40L monoclonal antibodies (CST, Danvers, MA, USA), and rabbit anti-human CD4 (Proteintech Group, Wuhan, China), mouse anti-human CD8 (Proteintech Group, Wuhan, China) antibody, rabbit anti-human FOXP3 monoclonal antibodies (CST, Danvers, MA, USA).

    Techniques: Cell Culture, Plasmid Preparation, Expressing, Transfection, Flow Cytometry, Infection, Co-Culture Assay, Standard Deviation